Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

17/02/2016 Barcelona Synchrotron Park, a Park with a (Pre)History 10/02/2016 New mechanism of anti-tumour action for the new drug developped at the UAB 03/02/2016 Step in Barcelona 27/01/2016 ALBA News 21/01/2016 SENER celebrates its 60th anniversary 15/01/2016 Parc Tecnològic del Vallès: Arrival of FERRER and Accreditation of SEVIBE CELLS
27 28 29 30 31 32 33 34 35 36 37